

Duffy blood system and g6pd genetic variants in *p. Vivax* malaria patients from manaus, Amazonas, Brazil

Natália Santos Ferreira

HEMOAM: Fundacao Hospitalar de Hematologia e Hemoterapia do Amazonas

Jéssica Lorena dos Santos Mathias

UFAM: Universidade Federal do Amazonas

Sérgio Roberto Lopes Albuquerque

HEMOAM: Fundacao Hospitalar de Hematologia e Hemoterapia do Amazonas

Anne Cristine Gomes Almeida

FMT-HVD: Fundacao de Medicina Tropical Doutor Heitor Vieira Dourado

Ana Carla Dantas

UFAM: Universidade Federal do Amazonas

Fernanda Cozendey Anselmo

HEMOAM: Fundacao Hospitalar de Hematologia e Hemoterapia do Amazonas

Emerson Silva Lima

UFAM: Universidade Federal do Amazonas

Marcus Vinicius Guimarães Lacerda

FMT-HVD: Fundacao de Medicina Tropical Doutor Heitor Vieira Dourado

Paulo Afonso Nogueira

ILMD Fiocruz Amazônia: Instituto Leonidas e Maria Deane Fiocruz Amazonia

Rajendranath Ramasawmy

FMT-HVD: Fundacao de Medicina Tropical Doutor Heitor Vieira Dourado

Marilda de Souza Gonçalves

Fiocruz Bahia: Centro de Pesquisas Goncalo Moniz

Jose Pereira Moura Neto (✉ jpmn@ufam.edu.br)

Universidade Federal do Amazonas <https://orcid.org/0000-0003-2177-7292>

Research

Keywords: malaria severe, G6PD, System Duffy, P. vivax

Posted Date: August 30th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-41862/v4>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background

Over a third of the world's population lives at risk of potentially severe *Plasmodium vivax* induced malaria. The unique aspect of the parasite's biology and interactions with the human host make it harder to control and eliminate the disease. Glucose-6-phosphate dehydrogenase (G6PD) deficiency and Duffy-negative blood groups are two red blood cell variations shown to confer protection against malaria.

Methods

Molecular genotyping of G6PD and Duffy was performed in 225 patients with severe and non-severe malaria randomly admitted at a reference center for infectious disease from Manaus. For G6PD variants characterization of the variants, Real Time PCR (qPCR) was performed, while Duffy genotyping by PCR-RFLP.

Results

Of the 225 patients, 29 (12.94%) and 43 (19.19%) were carriers of the G6PD c.202G > A and c.376A > G, respectively. For the Duffy genotype (c.-67T > C in the GATA promoter region), 70 (31.11%) were phenotyped as Fy(a + b-), 98 (43.55%) Fy(a + b+), 56 (24.9%) Fy(a-b+) and 1 (0.44%) Fy(a-b-). The *FY*01/FY*02* genotype was prevalent in both non-severe and severe malaria. In women, the *FY*01/FY*02* allele occurred concomitantly with c.376A > G more frequently in non-severe malaria, while in men, this combination was predominant in severe malaria. Duffy phenotype Fy(a-b+) ($p = 0.022$) and genotypes *FY*01/FY*01* / *FY*02/FY*02* ($p = 0.015$) correlated with high parasitemia density before and after treatment.

Conclusions

Our results showed only one uncomplicated *vivax* malaria patient with Duffy phenotype Fy(a-b-). Heterozygous GATA variants did not confer protection against malaria infection in this study. Research on G6PD and Duffy antigen deficiencies has been valuable, particularly when focused on densely populated areas. Our results confirm possible genetic molding mechanisms in *vivax* malaria in our Amazon region and can help to improve the understanding of the relationship between G6PD deficiency and Duffy genotypes concomitantly in the protection or susceptibility to *P. vivax* infection. Molecular diagnosis before treatment may be necessary in the Amazonian population, regardless of the diagnosis of uncomplicated or severe malaria.

Introduction

Malaria is one of the most serious public health problems worldwide. In the tropical and subtropical regions, this parasitic disease is the leading cause of social and economic problems (1, 2). In Brazil, approximately 90% of malaria cases result from *P. vivax* infection, and in 2018, over 33,000 cases were reported from the state of Amazonas (3).

Susceptibility to malarial infection includes individuals with repeated occurrence of the disease. The severity depends on the relationship between the host, its immunological vulnerability, the *Plasmodium* ssp. responsible for the infection, and the parasitic density. The clinical manifestation of malaria may include severe anemia, coagulation disorders, prominent thrombocytopenia, and numerical or functional changes in leukocytes with spleen involvement (4–6). In endemic regions of *P. vivax* infection, clinical complications and mortality have been reported and has led to the characterization of *P. vivax* malaria as a serious or even fatal disease; however, these findings are uncommon characteristics of previous infections (7, 8).

Although little is known of the pathophysiology, the progression and aggravation of *P. vivax* malaria is mainly associated with anemia, occasionally due to severe hemolysis (9–11). Other pathophysiological events, such as oxidative stress, may influence the development of clinical conditions (12, 13).

Some studies have cited that the Duffy glycoprotein acts as a possible facilitator in the process of erythrocyte invasion by *P. vivax*. Blood system antigens act as receptors for *P. vivax* merozoite ligands that contain Duffy-Binding-Like Domain (DBL) domains across

alleles. These Duffy blood group system antigens (Fy^a , Fy^b , $Fy3$, $Fy5$, and $Fy6$) are encoded by two co-dominant allelic forms $FY*01$ and $FY*02$ that differ by the single nucleotide polymorphism (SNP) in position c.125A > G of exon (14). The SNP located at position c.-67T > C in the GATA promoter region is characterized by the allele $FY*02N.01$ that silences the Fy^b expression in erythroid cells and homozygous individuals ($FY*02N.01 / FY*02N.01$) bear the $Fy(a-b-)$ phenotype that is known to be a protective factor against vivax malaria infection (15).

Another phenotype associated with weak Fy^b antigen expression is determined by SNP c.256C > T and c.298G > A. These polymorphisms occur within the first intracellular loop of the Duffy protein resulting in reduced expression of the Fy^b antigen. The frequency of Fy^b weak ($FY*02W.01$) is approximately 2% in Caucasians. Some polymorphisms resulting in Fy^a weak ($FY*01W.01$) allele have not been observed (16, 17).

Glucose 6-phosphate dehydrogenase (G6PD) is an enzyme involved in the pentose monophosphate pathway. Deficiency of this enzyme leads to free radical-mediated oxidative damage to erythrocytes, causing hemolysis. G6PD deficiency, linked to the inheritance of X chromosome(s) with disease causing variant(s), is mostly prevalent in people of African, Asian, and Mediterranean descent (18, 19). In females, there are selective advantages with G6PD A-, which is characterized by the combination of variants A376G (c.376A > G) with variants G202A (c.202G > A), A542T, G680T or T968C. The heterozygous state is suggested to offer women a selective advantage against severe malaria (20–22). G6PD deficiency is prevalent (8%) in populations where malaria is endemic (23).

The clinical severity between malaria endemic areas can be complex with multifactorial influence and genetic factors is one. In endemic areas of *P. vivax* malaria, comorbidities such as inherited hemoglobinopathies and G6PD deficiency are relevant to investigate as they may also be factors affecting phenotypic heterogeneity (24).

Vivax malaria is a challenge for control strategies and elimination (25). The unique parasite biology that involves the formation and subsequent reactivation of latent forms in the liver, and with the ability to infect vector before symptoms occur, favors the perpetuation of the parasitic life cycle (26). In this regard, there is added difficulty in tracking infected individuals owing to subpatent infections (27). This study aimed to determine the frequencies of Duffy alleles and G6PD c.202G > A and c.376A > G variants in malaria patients, to correlate with clinical signs, susceptibility, and resistance to acquired *P. vivax* infections.

Methodology

This study was based on a cross-sectional model. Blood samples and data from medical records were included from March 2013 to April 2016 period. Inclusion criteria were patients (> 18 years old) of any sexes and skin color with severe (hospitalized) or uncomplicated (outpatient) malaria without any associated disease. Patients were randomly admitted at the Tropical Medicine Foundation Dr. Heitor Vieira Dourado (FMT-HDV), a reference center for infectious disease in Manaus, capital of the Amazonas state, Brazil. All patients were treated at the Clinical Research Ward (PES CLIN) of the hospital. All the patients included in the study are unrelated individuals. Patients with comorbidities, hemoglobinopathies, mixed *Plasmodium* infections, and viral infections were excluded. Patients were classified as uncomplicated or severe malaria as described previously (28, 29), according to the World Health Organization (WHO) recommendations.

Approximately 0.5 mL of peripheral blood were collected in tube with an anticoagulant such as EDTA (ethylenediaminetetraacetic acid disodium salt) at a concentration of 1.5 mg / mL for blood counts. An aliquot of blood in 1.5 mL tubes were kept for extraction of nuclear DNA. An addition 0.6 mL was collected in a tube without anticoagulants for biochemical analyses. Immediately after blood collection, hematological determinations were performed on the automated counter - ABX Pentra 80 (Horiba Diagnostics, Montpellier, FR) and biochemistry was performed on a Beckman Coulter (Inc, CA, US).

The determination of parasitaemia was based on the count of asexual parasites per 200 white blood cells. The total number of leukocytes of each patient was used for the determination of the parasite density using the following formula (30):

$$\text{Parasite density}/\mu\text{L} = \frac{\text{Number of parasites} \times \text{Total white blood cells (WBC) counts}}{\text{Number of white blood cells (WBC) counted}}$$

Number of white blood cells (WBC) counted

DNA Analysis

DNA was extracted from 200 μ L of whole blood according to the QIAamp DNA Mini Kit (Qiagen, Hilden, DE) manufacturer's protocol (Cat No./ID 51304). After extraction, the DNA was quantified with a NanoDrop™ 2000 Spectrophotometer (Thermo Fisher Scientific, Massachusetts, EUA), and stored at -20°C.

Duffy Genotyping

The DNA amplification step was divided into two: a conventional PCR for amplification of the sequence of interest, followed by restriction enzyme digestion by PCR-RFLP, one for Duffy blood group (Duffy PCR) and one for the GATA Box variant (GATA PCR).

Genotyping for Duffy blood system groups was performed with synthetic oligonucleotides FYAB1 (5 'TCC CCC TCA ACT GAG AAC TC 3') and FAB2 (5 'AAG GCT GAG CCA TAC CAG AC 3'). Amplified products were visualized on a 1.5% agarose gel stained with ethidium bromide. After PCR amplification was confirmed, the products were processed with BanI restriction enzyme digestion and incubated for at least 4 hours at 37°C. The enzyme digestion product was electrophoresed on a 1.5% agarose gel stained with ethidium bromide for alleles discrimination.

Duffy genotypes as well as gene phenotypes were followed according to the FY (ISBT 008) Blood Group Alleles (31).

For verification of c.-67T > C SNP in the GATA Box promoter region, *FY*01/FY*02* and *FY*02/FY*02* genotype samples were used. Synthetic oligonucleotides FYN1 (5 'CAA GGC TGA CCC TA 3') and FYN2 (5 'CAT GGC ACC GTT TGG TTC AG 3') were used for the GATA PCR.

The GATA PCR product was treated with a *StyI* restriction enzyme and incubated for at least 4 hours at 37°C. The enzyme digestion product was observed on a 2.5% agarose gel. GATA normal genotypes appeared as 108 and 81bp bands, while GATA mutated showed an additional 61 bp band.

Samples with genotypes *FY*01/FY*01* and *FY*01/FY*02* were used to verify the SNPs c.265C > T and c.298G > A in the *FY*01W.02* coding region and for *Fy^x*.

The PCR product was treated with the restriction enzyme *MspAI* to verify the SNP c.265C > T and incubated for 4 hours at 60°C. For the SNP c.298G > A, the *MwoI* restriction enzyme was used and incubated for 4 hours at 37°C. Both were discriminated on an 8% polyacrylamide gel. The mutated genotypes for the SNP c.265C > T had an additional band of 161 bp and c.298G > A had an additional band of 343 bp.

G6PD Genotyping

For characterization of the variants, Real Time PCR (qPCR) was performed with the QuantStudio™ 3 Real-Time PCR System (Applied Biosystems, Thermo Fisher Scientific®) using TaqMan® probes specific for each polymorphism. The amplification reaction was performed for a final volume of 12 μ L/reaction, which contained 5 μ L of 2x TaqMan Universal Master Mix, 0.3 μ L of 20x SNP Genotyping Assay, 4.8 μ L of sterile water and 2.0 μ L of DNA (~ 100ng) of the sample. The G6PD variants analyzed in this project were chosen based on globally observed frequencies and their clinical importance according to WHO classifications. For qPCR Technique, we used the (A-) VAL68MET (202G > A) (rs1050828) and (A+) ASN126ASP (376A > G) (rs1050829) probes. To confirm the mutations found, amplification of the relevant DNA segments by PCR followed by DNA sequencing (ABI 3100, Applied Biosystems, Foster City, CA) (32) were performed.

Statistical Analysis

Data were entered into a database using Graphpad-Prism 5.0 software (Graphpad Software, San Diego, CA-US) and IBM SPSS Statistics, version 19 (IBM Corp., Armonk, NY, US), organized by variable type. The analysis of qualitative or categorical variables of three or more groups was performed by the non-parametric Chi-square test (χ^2), corrected by the Mantel-Haenszel and Yates tests. The analysis of groups with only two categorical variables were performed with the Fisher's exact test. Confidence intervals of 95% and prevalence ratios were calculated for these variables. The Hardy-Weinberg equilibrium (HWE) was tested by comparing observed genotypes to expected genotypes frequencies by chi-square test.

Results

A total of 225 patients diagnosed with *P. vivax* malaria were included in the study. 97 patients (43.1%) had uncomplicated and 128 (56.9%) severe malaria. Table 1 showed the epidemiological and physical parameters for uncomplicated and severe *P. vivax* malaria stratified by gender. Most severe malaria male cases had Pallor (82.5%), Choluria (77.8), Headache (76.2%), Anorexia (74.6%) and Hepatosplenomegaly (71.4%). Among the female patients, Headache (92.9%), Anorexia (85.7%), Pallor (83.3%), Vomiting (83.3%) and Choluria (73.8%) were the common symptoms.

Table 1
Epidemiological clinical parameters for uncomplicated and severe *P. vivax* malaria patients from Manaus, Amazon.

Clinical Signs	FEMALE			MALE		
	Severe	Uncomplicated	p-value	Severe	Uncomplicated	p-value
	(n = 60) %	(n = 47) %		(n = 68) %	(n = 50) %	
Abdomen Pain	43	35 ↑	.461	44	33 ↑	.521
Severe Anemia	13 ↑	01	.002	11 ↑	01	< .001
Anorexia	51 ↑	35	.132	51 ↑	37	.533
Choluria	44 ↑	23	.008	53 ↑	21	< .001
Cough	24 ↑	16	.334	21	16 ↑	.526
Diarrhoea	17 ↑	12	.460	28 ↑	18	.353
Dyspnoea	20 ↑	23	.075	24	18 ↑	.544
Epistaxis	03	05 ↑	.231	03	10 ↑	.008
Headache	56 ↑	39	.084	51	46 ↑	.013
Haemoglobinuria	11 ↑	06	.305	14 ↑	03	.021
Hepatosplenomegaly	39 ↑	20	.016	49 ↑	14	< .001
Jaundice	43 ↑	09	< .001	43 ↑	12	< .001
Leukocyturia	20	18 ↑	.371	30 ↑	08	< .001
Obesity	05 ↑	05	.467	09 ↑	01	.028
Oliguria	09 ↑	04	.237	10 ↑	04	.206
Pallor	50 ↑	33	.083	56	43 ↑	.393
Petechia	03	11 ↑	.005	03 ↑	05	.204
Vomiting	50	40 ↑	.509	44	36 ↑	.262
Whole Blood Transfusion	10 ↑	04	.170	18 ↑	03	< .001
Independent – Samples T-tests Post Hoc/ Bonferroni test ↑↓: Increase or decrease of frequency N: cases						
N: Cases ^a Fischer Test ^b χ^2 test (Yates's corrected)						

The biochemical and hematological parameters in the *P. vivax* infected patients are shown in Table 2. As expected, significance decrease of RBC, Hemoglobin and hematocrit and high bilirubin levels was observed. Male patients with severe malaria presented lowest Hematological values ($P < 0.001$).

Table 2

Hematological and biochemical parameters for uncomplicated and severe *P. vivax* malaria patients from Manaus, Amazon.

	FEMALE			MALE		
	Severe (n = 60)	Uncomplicated (n = 47)	p- value	Severe (n = 68)	Uncomplicated (n = 50)	p- value
Age, median	37.07 ± 12.45	35.36 ± 13.76	.402	39.43 ± 13.45	25.01 ± 19.39	.770
Temperature, median	37.25 ± 0.79	37.13 ± 0.89	.908	36.95 ± .74	36.62 ± 0,91	.623
Weight (Kg)	56.47 ± 17.91	62.45 ± 16.09	.561	51.89 ± 24.07	58.30 ± 15.90	.537
Numbers of days in hospital	2.80 ± 1.56	3.68 ± 3.43	.363	3.51 ± 2.40	5.93 ± 7.61	.277
Asexual Parasite Density	15735.4 ± 13276.2	8597.3 ± 9176.5	.032	5264.4 ± 9994.7	8760.1 ± 11474.1	.318
Parasitaemia	344.53 ± 207.06	302.91 ± 201.67	.404	169.80 ± 209.01	229.63 ± 181.54	.591
Platelet Count x10 ⁹ /L	59.94 ± 46.06	87.36 ± 77.78	.079	125.42 ± 113.01	109.19 ± 73.95	.428
WBC x10 ³ ul	5.27 ± 2.01	5.56 ± 2.21	.542	7.67 ± 4.03	5.78 ± 2.35	.010
RBC x10 ⁶ ul	3.51 ± 0.89	3.98 ± 0.75	.008	3.48 ± 1.12	4.46 ± 0.74	< .001
Hemoglobin (g/dl)	99.72 ± 2.42	11.33 ± 2.15	.042	10.06 ± 2.94	12.71 ± 2.01	< .001
Hematocrit (%)	30.45 ± 7.75	35.95 ± 6.95	.029	30.22 ± 8.97	39.62 ± 6.17	< .001
MCV (fL)	87.72 ± 5.57	86.13 ± 5.64	.240	88.68 ± 8.83	89.05 ± 4.34	.790
MCH (pg)	28.94 ± 2.84	27.94 ± 2.05	.086	29.56 ± 3.14	28.57 ± 1.94	.081
MCHC (g/dl)	32.99 ± 1.77	32.46 ± 1.43	.166	33.65 ± 1.59	32.09 ± 1.72	< .001
Reticulocytes (%)	1.71 ± 2.16	1.75 ± 1.41	.951	4.48 ± 4.84	3.18 ± 4.14	.371
Direct bilirubin (mg/dL)	7.02 ± 7.68	3.76 ± 8.29	.127	3.61 ± 4.78	6.84 ± 7.26	.023
Indirect bilirubin (mg/dL)	4.90 ± 5.58	2.62 ± 5.79	.133	6.41 ± 8.73	11.86 ± 9.91	.012
Total bilirubin (mg/dL)	12.50 ± 13.46	7.81 ± 16.58	.239	10.36 ± 12.56	19.97 ± 17.94	.007
Urea (mg/dL)	33.06 ± 14.20	30.63 ± 16.84	.829	61.45 ± 35.63	36.86 ± 13.75	< .001
Creatinine (mg/dL)	0.81 ± 0.34	0.88 ± 0.38	.426	1.40 ± 0.94	1.02 ± 0.34	.022
Lactate dehydrogenase (U/L)	855.86 ± 339.73	548.95 ± 173.95	< .001	921.06 ± 524.01	650.07 ± 235.41	.072
Alkaline Phosphatase (IU/L)	260.41 ± 169.77	251.24 ± 148.09	.823	232.53 ± 132.78	127.85 ± 114.66	< .001
Ca ⁺⁺ (mM)	8.64 ± 0.80	8.85 ± 0.99	.466	8.73 ± 1.21	9.33 ± 0.89	.130
K ⁺ (mM)	3.66 ± 0.49	3.92 ± 0.41	.079	3.99 ± 0.59	3.97 ± 0.45	.938
Glucose mg/dL	88.82 ± 32.71	97.58 ± 28.06	.255	99.20 ± 35.03	101.44 ± 33.65	.773
Independent – Samples T-tests Post Hoc/ Bonferroni test Continuous variables are presented as mean ± SD N: Cases						
WBC: White Blood Cells RBC: Red Blood Cells MCV: Mean corpuscular volume						
MCH: Mean corpuscular hemoglobin MCHC: Mean corpuscular hemoglobin concentration						

Genotyping of 29 patients (11 women and 18 men) were positive for the G6PD c.202G > A variant. Ten women (4.44%) and one (0.44%) were heterozygous and homozygous, respectively. Among the male patients, 18 (8.0%) were hemizygous males. The c.376A > G was identified in 43 (19.11%) patients. 18 women (8.0%) were heterozygous and 02 (0.88%) homozygous. 23 (10.22%) were hemizygous males. Both SNPs were in HWE as calculated from the frequencies of the alleles among the females as the G6PD gene is located on the X chromosome. The G6PD mutations in the clinical perspective, however, is better explain in male patients as male individual is either deficient or normal (33).

Analysis of the Duffy system showed a phenotypic distribution of 70 (31.10% - Fy(a + b-), 96 (42.70%) - Fy(a + b+), 56 (24.89%) - Fy(a-b+) and 1 (0.44%) - Fy(a-b-) among the 225 malaria patients. Table 3 shows the genotypic distribution for the Duffy system.

Table 3
Allele frequency of the Duffy blood group from *vivax* malaria patients.

Phenotypes	Genotypes	Percentage (%)
Fy(a + b+)	<i>FY * 01 / FY * 02</i>	42.70
Fy(a + b-)	<i>FY * 01 / FY * 02N.01</i>	16.0
	<i>FY * 01 / FY * 01</i>	15.10
Fy(a-b+)	<i>FY * 02 / FY * 02</i>	16.0
	<i>FY * 02 / FY * 02N.01</i>	8.88
Fy(a + ^w)	<i>FY*01 / FY * 01W.02</i>	0.88
Fy(a-b-)	<i>FY * 02N.01 / FY * 02N.01</i>	0.44

The genotype *FY*01/FY*02* was predominant in the population and was present at higher frequencies in both uncomplicated and severe malaria, 45.3% and 39.2%, respectively (Fig. 1).

For c.202G > A, the highest frequency was among females with the Fy(a + b+) and Fy(a + b-) phenotype in severe malaria cases compared with the Fy(a-b+) phenotype, that was frequent among cases of uncomplicated malaria. In males, all Duffy phenotypes were more frequent in severe malaria, with Fy(a + b-) representing the largest number of cases. For c.376A > G, we observed a higher number of cases with the polymorphism for the Fy(a + b) phenotype in patients with severe malaria, with 47.36% of cases reported in males (data not shown).

The *FY*02N.01/FY*02N.01*, responsible for the Fy(a-b-) phenotype, was found in only one patient (female) with uncomplicated malaria and was is not carrier of the G6PD variants. Among patients with uncomplicated malaria, the frequency of c.202G > A and c.376A > G variants decreased, particularly when these polymorphisms were concomitant. Severe malaria patients showed no variations in frequency for the c.202G > A variant. However, in the presence of A376G there was a slight decrease in frequency. When combined with the GATA variant, the c.202G > A and c.376A > G variants were observed at a lower frequency in uncomplicated malaria (Table 4). For severe malaria, the presence of the combined polymorphisms showed a moderate variation in frequency (Fig. 2).

Table 4

Genotypic frequency distribution of G6PD variants among uncomplicated and severe *P. vivax* malaria patients by the presence of Duffy GATA normal or mutated variants.

Malaria	Duffy GATA	G202A		p- value	A376G		p-value	G202A / A376G		p-value
		N	(%)		N	(%)		N	(%)	
		202wt	c.202G >A	376wt	c.376A >G	202wt/376wt	c.202G > A/c.376A >G			
Uncomplicated	Normal	86 (94.5)	05 (5.5)	.487**	86 (88.7)	11 (11.3)	.452**	86 (97.7)	02 (2.3)	.531**
	Mutated	24 (92.3)	02 (7.7)		24 (92.3)	02 (7.7)		24 (96.0)	01 (4.0)	
Severe	Normal	45 (77.6)	13 (22.4)	.181*	45 (70.3)	19 (29.7)	.252*	45 (83.3)	09 (16.7)	.107*
	Mutated	17 (65.4)	09 (34.6)		17 (60.7)	11 (39.3)		17 (68.0)	08 (32.0)	
Total	Normal	131 (87.9)	18 (12.1)	.087*	131 (81.4)	30 (18.6)	.249*	131 (92.3)	11 (7.7)	.043*
	Mutated	41 (78.8)	11 (21.2)		41 (75.9)	13 (24.1)		41 (82.0)	09 (18.0)	

wt: Wild Type N: cases * χ^2 test (Yates's corrected) ** Fisher's exact test

No significant association was observed between the mutated Duffy alleles and *P. vivax* infection among the females. The participants' ethnicity is difficult to assess. There is a strong regional ancestral mix among the Amazonian Caboclos that originated with the arrival of Caucasians and African-Brazilian to indigenous lands.

The Duffy phenotype Fy(a-b+) ($p = 0.022$) and genotypes FY*01/FY*01 / FY*02/FY*02 ($p = 0.015$) correlated with high parasitemia density (Figs. 3, 4).

Discussion

Hypoglycemia (< 70 mg/dL) has been detected in approximately 16% of patients and is considered a clinical and laboratory features of severe malaria (34). Careful glucose monitoring should be targeted to these complications, especially in those patients with G6PD deficiency. However, none of the G6PD alleles segregated with low level glucose among the severe malaria patients.

In this study, we found in uncomplicated malaria patients a three times higher frequency of genotype FY*01/FY*02 (45.3%) when compared to the FY*01/FY*01 (15.4%) and FY*02/FY*02 (14.8%). In severe malaria patients, the frequency of genotype FY*01/FY*02 (39.2%) was approximately two times higher with regards to the genotypes FY*01/FY*02N.01 (20.6%) and FY*02/FY*02 (17.5%). These findings corroborate to the study reported by Cavasini et al. (2007), that correlated the high frequency of the FY*01 and FY*02 alleles among *P. vivax* malaria patients. The FY*01/FY*02 and FY*01/FY*01 genotypes were associated with a high frequency of *P. vivax* infection suggesting that these individuals have a higher risk of developing disease (35). The FY*01/FY*01 and FY*01/FY*02 genotypes are associated with increased frequency of *P. vivax* infection, while FY*01/ FY*02W.01 and FY*02/ FY*02W.01 were associated with low parasitic density levels (17).

The presence of a single case with null Duffy variants in this study supports a possible advantageous selection, driven by defense mechanisms against *P. vivax*. In endemic areas, the Duffy negative blood group is reported as a protective factor against *P. vivax* malaria infection (36). In a study conducted in São Paulo, the phenotypic frequencies found in blood donors for Duffy blood system

antigens were 19.8% for the phenotype Fy(a + b-) in Caucasians and 14.0% in African-Brazilian, Fy(a + b+) in 41.4% of Caucasians and 1.6% of African-Brazilian, Fy(a-b+) in 37.8% of Caucasians and 17.5% of African-Brazilian and Fy(a-b-) in 1.1% of Caucasians and 66.9% of African-Brazilian (37). Our results indicate that the Manaus-Amazonas region has individuals who express three Duffy phenotypes Fy(a + b+), Fy(a + b-) and Fy(a-b+) more frequently with expression of *FY*01* and *FY*02* antigens.

For the process of parasite invasion into red blood cells, Duffy protein is functionally important. In regions of high malaria transmission rates, as in the inhabitants of the Amazon, Duffy protein is naturally immunogenic. Woolley et al. demonstrated (in *vitro*) that the expression level of the *Fy6* epitopes was significantly lower in reticulocytes and red blood cells from individual carriers of the FYB/FYB genotypes compared with individuals of the FYA/FYA or FYA/FYB genotypes. Another similar study showed that the presence of the *FY*02N.01* allele resulted in a 50% reduction of that protein on invasion by *P. vivax* (38, 39).

In a study with *P. vivax* malaria patients, the *FY*01* and *FY*02* alleles were found to have low, medium, and high parasitic density. However, in the presence of the GATA variant, genotypes with alleles *FY*02N.01* and *FY*02W.01* were found only in patients with low parasitic density and low symptomatology (17).

A study performed in the state of Pará with a population of African descent demonstrated the presence of the c.202G > A variant was 0.060, the Duffy blood group included 24.3% Duffy negative and 41.3% individuals heterozygous for *FY*02^w*. The frequency of the *FY*02^w* allele was 41.0%. These findings support the monitoring of individuals with G6PD deficiency for use of primaquine during the routine care of Afro-descendant communities of the Trombetas, Erepecuru, and Cumná rivers, to assess risks of hemolytic crisis in recurrent cases of malaria in the region (40).

Several studies have revealed that the phenotypic and genotypic variation complexity of the Duffy system and the variants of G6PD (A-) can have a significant impact on the distribution of human populations in areas where malaria is endemic. The Duffy system and G6PD are polymorphic systems that offer great challenges to researchers not only due to their academic importance, but also due to their potential applications in the treatment of vivax malaria (41). Whenever natural selection occurs within a population in an area of endemicity for malaria, natural adaptations may result from genetic variation that provides a partial defense mechanism against *P. vivax* infections (38).

In this study, we were careful to include hemoglobinopathies status like sickle cell anemia (HbSS) or Sickle cell diseases (HbSC, HbSD, HbSE) of the patients before antimalarial treatment intervention.

One of the major confounders of our analysis and limitations in this study is the inherent disadvantage of G6PD deficiency that goes against the consensus that G6PD potentially protect against malaria. Despite most G6PD-deficient persons are asymptomatic, a hemolytic anemia, main clinical sign, can occur 1–3 days after exposure, eating fava beans, triggered by infections or by certain drugs, such as those used to treat malaria (42, 43). In many cases, this acute hemolytic anemia is usually self-limiting and resolve on their own (44). In addition, we acknowledge that an important limitation of our analysis is the small sample size and we understand that additional studies of larger samples will be required to confirm our results.

Conclusion

This study reports the frequency concomitantly of G202A and A376G variants and Duffy alleles in patients with severe and uncomplicated malaria in Manaus, Amazonas, Brazil.

Before treatment, molecular diagnosis for the G202A and A376G variants in patients diagnosed with malaria may be necessary in the Amazonian population.

The *FY*01/FY*02* Duffy genotypes was more frequent than the null expression genotype in the vivax malaria patients and the *FY*01/FY*02* genotype demonstrated greater association with severe malaria cases.

We found one only of the uncomplicated vivax malaria patient with Duffy phenotype Fy(a-b-).

Heterozygous GATA variants do not confer protection against malaria infection.

Duffy phenotype Fy(a-b+) and genotype *FY*02/ FY*02* presented the highest values parasitemia density of the vivax malaria.

Uncomplicated malaria showed a greater frequency of variation for GATA and G6PD variants than severe malaria.

Declarations

ACKNOWLEDGMENTS

We especially thank to all patients involved in this study and staff of the Molecular Biology Laboratory of the Federal University of Amazonas (UFAM) and Foundation of Tropical Medicine (FMT-HD) for the medical and technical support. Finally, the authors thank the Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) for financial support.

AUTHORS' CONTRIBUTIONS

- Natália Santos Ferreira and Jéssica Lorena dos Santos Mathias performed the collection of samples and performed the practical and laboratorial parts of the entire project.
 - Natalia Santos Ferreira, Jéssica Lorena dos Santos Mathias and Anne Cristine Gomes Almeida performed the molecular tests for the genotyping of G6PD and Duffy genes polymorphisms. It should be noted that this project was the dissertation for his Master's Degree of Natalia Santos Ferreira and Jéssica Lorena dos Santos Mathias.
 - Ana Carla Dantas and Fernanda Cozendey Anselmo assisted in the collection of samples and digitization of results in data analysis programs.
 - Sérgio Roberto Lopes Albuquerque, Marcus Vinicius Guimarães Lacerda and Emerson Silva Lima assisted wrote the manuscript with support from Jose Pereira de Moura Neto.
 - Marilda de Souza Gonçalves, Paulo Afonso Nogueira, Sérgio Roberto Lopes Albuquerque, Rajendranath Ramasawmy and Marcus Vinicius Guimarães Lacerda assisted in the development of the project and contributed to the final version of the manuscript.
 - José Pereira de Moura Neto conceived the study, was the idealizer of the project and advised Natalia Santos Ferreira and Jéssica Lorena dos Santos Mathias. He helped supervise the project and assisted in sample collection and performed the analytical calculations and results simulations.
- The authors declare no conflict of interest and have no have financial relations with the industry. All donors were volunteers and provided (or a legal guardian provided) informed, written consent.

FUNDING

This work was supported by grants from Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM). Protocol Number: 1094/2013-FAPEAM; Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

AVAILABILITY OF DATA AND MATERIALS

The full data used to support the findings of this study, including, consent terms, electronic files, as well as the lab techniques and materials used may be released upon reasonable request to my Institutional email address: jpmn@ufam.edu.br.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

This research was initiated after approval by the Research Ethics Committee (CEP) of the FMT-HVD. To ensure patient welfare, all the patients included in the study signed the Free and Clarified Commitment Term (FICF), in compliance with CNS Resolutions 196/96.

The samples were from a larger study entitled "Clinical characterization of malaria complicated by *Plasmodium vivax*", approved by the National Commission for Ethics in Research (CONEP), in June 2009, opinion n°. 343/2009, protocol n° 25.000.011.792 / 2009-15. This new project was approved by the Research Ethics Committee of (FMT-HVD) (study number 343/2009) entitled "Study of DUFFY Polymorphisms in patients infected with *Plasmodium vivax*" with opinion no. CAAE-0004.0.112.000-11 on 12/29/2011.

CONSENT FOR PUBLICATION

Not applicable.

CONFLICT OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Greenwood BM, Fidock DA, Kyle DE, et al. Malaria: progress, perils, and prospects for eradication. *J Clin Invest*. 2008;118(4):1266-1276. doi:10.1172/JCI33996.
2. World Health Organization. World Malaria Report. Geneva: WHO; 2015.
3. Ministério Da Saúde. Secretaria De Vigilância Em Saúde. Departamento De Doenças Transmissíveis. Coordenação Geral Dos Programas Nacionais De Controle E Prevenção. Dados de 2018. Sivep malária/Svs.
4. Akinosoglou KS, Solomou EE, Gogos CA. Malaria: a haematological disease. *Hematology*. 2012;17(2):106-114. doi:10.1179/102453312X13221316477336.
5. Kochar DK, Das A, Kochar SK, Saxena V, Sirohi P, Garg S, Kochar A, Khatri MP, Gupta V. Severe *Plasmodium vivax* malaria: a report on serial cases from Bikaner in northwestern India. *Am J Trop Med Hyg*. 2009 Feb;80(2):194-8. PMID: 19190212.
6. Oliveira-Ferreira J, Lacerda MV, Brasil P, Ladislau JL, Tauil PL, Daniel-Ribeiro CT. Malaria in Brazil: an overview. *Malar J*. 2010;9:115. Published 2010 Apr 30. doi:10.1186/1475-2875-9-115.
7. Lacerda MV, Mourão MP, Alexandre MA, et al. Understanding the clinical spectrum of complicated *Plasmodium vivax* malaria: a systematic review on the contributions of the Brazilian literature. *Malar J*. 2012;11:12. Published 2012 Jan 9. doi:10.1186/1475-2875-11-12.
8. Baird JK. Evidence and implications of mortality associated with acute *Plasmodium vivax* malaria. *Clin Microbiol Rev*. 2013;26(1):36-57. doi:10.1128/CMR.00074-12.
9. Alexandre MA, Ferreira CO, Siqueira AM, et al. Severe *Plasmodium vivax* malaria, Brazilian Amazon. *Emerg Infect Dis*. 2010;16(10):1611-1614. doi:10.3201/eid1610.100685.
10. Quintero JP, Siqueira AM, Tobón A, et al. Malaria-related anaemia: a Latin American perspective. *Mem Inst Oswaldo Cruz*. 2011;106 Suppl 1(Suppl 1):91-104. doi:10.1590/s0074-02762011000900012.
11. Douglas NM, Anstey NM, Buffet PA, et al. The anaemia of *Plasmodium vivax* malaria. *Malar J*. 2012;11:135. Published 2012 Apr 27. doi:10.1186/1475-2875-11-135.
12. Carvalho BO, Lopes SC, Nogueira PA, et al. On the cytoadhesion of *Plasmodium vivax*-infected erythrocytes. *J Infect Dis*. 2010;202(4):638-647. doi:10.1086/654815.
13. Yeo TW, Lampah DA, Tjitra E, et al. Greater endothelial activation, Weibel-Palade body release and host inflammatory response to *Plasmodium vivax*, compared with *Plasmodium falciparum*: a prospective study in Papua, Indonesia. *J Infect Dis*. 2010;202(1):109-112. doi:10.1086/653211.
14. Miller LH, Mason SJ, Clyde DF, McGinniss MH. The resistance factor to *Plasmodium vivax* in blacks. The Duffy-blood-group genotype, FyFy. *N Engl J Med*. 1976;295(6):302-304. doi:10.1056/NEJM197608052950602.
15. Tournamille C, Colin Y, Cartron JP, Le Van Kim C. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. *Nat Genet*. 1995;10(2):224-228. doi:10.1038/ng0695-224.
16. Albuquerque SR, Cavalcante Fde O, Sanguino EC, et al. FY polymorphisms and *vivax* malaria in inhabitants of Amazonas State, Brazil. *Parasitol Res*. 2010;106(5):1049-1053. doi:10.1007/s00436-010-1745-x.
17. Abou-Ali, R.K., Dhyani, A., Terço, A.L. *et al*. Impact of Duffy polymorphisms on parasite density in Brazilian Amazonian patients infected by *Plasmodium vivax*. *Malar J* **18**, 289 (2019). <https://doi.org/10.1186/s12936-019-2918-4>.
18. Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. *Blood Cells Mol Dis*. 2009;42(3):267-278. doi:10.1016/j.bcmd.2008.12.005.
19. Luzzatto L. G6PD deficiency and malaria selection. *Heredity (Edinb)*. 2012;108(4):456. doi:10.1038/hdy.2011.90.
20. Sirugo G, Predazzi IM, Bartlett J, Tacconelli A, Walther M, Williams SM. G6PD A- deficiency and severe malaria in The Gambia: heterozygote advantage and possible homozygote disadvantage. *Am J Trop Med Hyg*. 2014;90(5):856-859. doi:10.4269/ajtmh.13-

21. Manjurano A, Sepulveda N, Nadjm B, Mtove G, Wangai H, Maxwell C, Et Al. African Glucose-6-Phosphate Dehydrogenase Alleles Associated with Protection from Severe Malaria in Heterozygous Females in Tanzania. *PlosGenet*. 2015;11:E1004960. Doi: 10.1371/Journal.Pgen.1004960.
22. Nafa K, Reghis A, Osmani N, et al. At least five polymorphic mutants account for the prevalence of glucose-6-phosphate dehydrogenase deficiency in Algeria. *Hum Genet*. 1994;94(5):513-517. doi:10.1007/BF00211017.
23. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, Et Al. G6PD Deficiency Prevalence and Estimates of Affected Populations in Malaria Endemic Countries: A Geostatistical Model-Based Map. *PlosMed*. 2012;9:E1001339. Doi: 10.1371/Journal.Pmed.1001339.
24. Ramos Júnior WM, Sardinha JF, Costa MR, Santana MS, Alecrim MG, Lacerda MV. Clinical aspects of hemolysis in patients with *P. vivax* malaria treated with primaquine, in the Brazilian Amazon. *Braz J Infect Dis*. 2010;14(4):410-412. doi:10.1590/s1413-86702010000400017.
25. Hedrick PW. Population genetics of malaria resistance in humans [published correction appears in *Heredity* (Edinb). 2011 Dec;107(6):602]. *Heredity (Edinb)*. 2011;107(4):283-304. doi:10.1038/hdy.2011.16.
26. Adams JH, Mueller I. The Biology of *Plasmodium vivax*. *Cold Spring Harb Perspect Med*. 2017;7(9):a025585. Published 2017 Sep 1. doi:10.1101/cshperspect.a025585.
27. Adapa SR, Taylor RA, Wang C, Thomson-Luque R, Johnson LR, Jiang RHY. *Plasmodium vivax* readiness to transmit: implication for malaria eradication. *BMC Syst Biol*. 2019;13(1):5. Published 2019 Jan 11. doi:10.1186/s12918-018-0669-4.
28. World Health Organization. Guidelines for the treatment of malaria. Second Edition ed: World Health Organization; 2010.
29. Severe malaria. *Trop Med Int Health*. 2014 Sep;19 Suppl 1:7-131. doi: 10.1111/tmi.12313_2. PMID: 25214480.
30. https://www.paho.org/bra/index.php?option=com_docman&view=document&slug=ravreda-newsletter-out-dez-2004-6&layout=default&alias=766-ravreda-newsletter-out-dez-2004-6&category_slug=malaria-972&Itemid=965. Accessed 2020.
31. ISBT http://www.isbtw eb.org/filea dmin/user_uploa d/Worki ng_parti es/WP_on_Red_Cell_Immun ogene tics_and/008_FY_Allel es_v4.1.pdf. Accessed 2020.
32. Neto, J. P. et al. "A novel c.197T @ A variant among Brazilian neonates with glucose-6-phosphate dehydrogenase deficiency." *Genet. Mol. Biol.* [online]. 2008, vol.31, n.1, pp.33-35. ISSN 1678-4685. <https://doi.org/10.1590/S1415-47572008000100006..>
33. Domingo GJ, Advani N, Satyagraha AW, et al. Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities. *Int Health*. 2019;11(1):7-14. doi:10.1093/inthealth/ihy060.
34. Siqueira AM, Lacerda MV, Magalhães BM, et al. Characterization of *Plasmodium vivax*-associated admissions to reference hospitals in Brazil and India. *BMC Med*. 2015;13:57. Published 2015 Mar 20. doi:10.1186/s12916-015-0302-y
35. Cavasini CE, Mattos LC, Couto AA, et al. *Plasmodium vivax* infection among Duffy antigen-negative individuals from the Brazilian Amazon region: an exception? *Trans R Soc Trop Med Hyg*. 2007;101(10):1042-1044. doi:10.1016/j.trstmh.2007.04.011.
36. Howes RE, Patil AP, Piel FB, et al. The global distribution of the Duffy blood group. *Nat Commun*. 2011;2:266. doi:10.1038/ncomms1265.
37. Novaretti MC, Dorliac-Llacer PE, Chamone DA. Estudo De Grupos Sanguíneos Em Doadores De Sangue Caucasóides e Negróides Na Cidade De São Paulo. *Rev. Bras. Hematol. Hemoter*. v.22 n.1 São José do Rio Preto jan./abr. 2000. <https://doi.org/10.1590/S1516-84842000000100004>.
38. Ceravolo IP, Sanchez BA, Sousa TN, et al. Naturally acquired inhibitory antibodies to *Plasmodium vivax* Duffy binding protein are short-lived and allele-specific following a single malaria infection. *Clin Exp Immunol*. 2009;156(3):502-510. doi:10.1111/j.1365-2249.2009.03931.x.
39. Woolley IJ, Hotmire KA, Sramkoski RM, Zimmerman PA, Kazura JW. Differential expression of the duffy antigen receptor for chemokines according to RBC age and FY genotype. *Transfusion*. 2000 Aug;40(8):949-53. doi: 10.1046/j.1537-2995.2000.40080949.x. PMID: 10960522.
40. Oliveira HSS, Silva ANLMD, Andrade GB, Gaia KC, Costa GLC, Santos ÂKCRD, Guerreiro JF. Molecular genotyping of G6PD mutations and Duffy blood group in Afro-descendant communities from Brazilian Amazon. *Genet Mol Biol*. 2018 Oct-Dec;41(4):758-765. doi: 10.1590/1678-4685-GMB-2017-0253. Epub 2018 Nov 29.
41. Tran TM, Oliveira-Ferreira J, Moreno A, Santos F, Yazdani SS, Chitnis CE, Altman JD, Meyer EV, Barnwell JW, Galinski MR. Comparison of IgG reactivities to *Plasmodium vivax* merozoite invasion antigens in a Brazilian Amazon population. *Am J Trop*

42. Luzzatto L, Poggi V. Glucose-6-phosphate dehydrogenase deficiency. In: Nathan and Oski's Hematology and Oncology of Infancy and Childhood: Expert, 8th ed. Orkin SH, Nathan DG, Ginsburg D, Look AT, Fisher DE, Lux SE, editors. 2015 Elsevier Saunders, Philadelphia, PA. pp. 609-629e.6.
43. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI. G6PD deficiency: global distribution, genetic variants and primaquine therapy. *Adv Parasitol.* 2013;81:133-201. doi: 10.1016/B978-0-12-407826-0.00004-7. PMID: 23384623.
44. Youngster I, Arcavi L, Schechmaster R, Akayzen Y, Popliski H, Shimonov J, Beig S, Berkovitch M. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. *Drug Saf.* 2010 Sep 1;33(9):713-26. doi: 10.2165/11536520-000000000-00000. PMID: 20701405.

Figures




Figure 1

Genotypic and phenotypic distribution of Duffy antigens among uncomplicated and severe *P. vivax* malaria patients. The genotypes with null and weak expression of Duffy System were found in patients with uncomplicated malaria and the FY*01/FY*02 genotype demonstrated greater association with severe malaria cases.




Figure 2

Distribution of c.202G>A and c.376A>G variants in the presence and absence of the Duffy variant among *P. vivax* malaria patients. The top panel shows that the presence of G202A and A376G variants were more frequent in cases of severe vivax malaria, with the lowest frequencies in uncomplicated malaria cases concomitant with the presence of other variants. On the lower panel, the GATA variant has been associated with virtually all records of GATA / G6PD variants in severe vivax malaria cases. WT: Wild Type




Figure 3

Parasitemia in *P. vivax* malaria patients and Duffy phenotypes. There was statistical significance ($p=0.022$) for parasitic density, mainly in the phenotype Fy(a-b+).




Figure 4

Parasitemia in *P. vivax* malaria patients and Duffy genotypes. The FY*02/ FY*02 genotype had the highest parasitic values, and when an FY*02 allele was present and expressed, these values were higher. The parasitic density was lower in the presence of the GATA variant.